Clinical trials: Atorvastatin
- Drug or intervention Atorvastatin
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Healthy
A Study of LY3502970 in Healthy Participants
The main purposes of this study are to determine: The safety of LY3502970 and any side effects that might be associated with it. How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.
- Trial name
- NCT03929744
- Testing
- LY3502970, Atorvastatin, Simvastatin
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atherosclerotic Cardiovascular Disease
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
This study aims to confirm the effectiveness of ezetimibe add-on therapy on LDL-C levels compared to atorvastatin monotherapy, especially in very high-risk patients.
- Trial name
- BETTER (NCT05761444)
- Testing
- Atozet 10/40 mg or 10/80 mg, Lipitor 40 mg or 80 mg
- Where
- 7 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Organon and Co
Healthy Adults
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult…
- Trial name
- NCT05093205
- Testing
- PF-06882961, Atorvastatin, Midazolam
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of LY3478045 in Healthy Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3478045 and any side effects that might be associated with it.
- Trial name
- NCT04270370
- Testing
- LY3478045, Atorvastatin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Primary Hypercholesterolemia
Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)
The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose low-density lipoprotein (LDL)-cholesterol levels…
- Trial name
- NCT00871351
- Testing
- Ezetimibe, Atorvastatin, Rosuvastatin
- Volunteers
- 125 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in Korea.
- Trial name
- NCT00166504
- Testing
- ezetimibe (+) simvastatin, atorvastatin
- Volunteers
- 203 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
- Trial name
- NCT00442897
- Testing
- simvastatin (+) ezetimibe, Comparator: atorvastatin
- Volunteers
- 229 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and atorvastatin in participants with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol target with…
- Trial name
- NCT00654095
- Testing
- Ezetimibe, atorvastatin
- Volunteers
- 146 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Metabolic Syndrome
Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)
A 6-week clinical trial in patients with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease to study the effects of ezetimibe/simvastatin and atorvastatin on lipids.
- Trial name
- NCT00409773
- Testing
- ezetimibe (+) simvastatin, Comparator: atorvastatin calcium
- Volunteers
- 1,143 people
- Sponsor
- Organon and Co
Hypercholesterolemia
A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)
To evaluate the percentage of patients with either established cardiovascular disease (CVD), at "high risk" of developing CVD or with diabetes who are on simvastatin 40mg, with fasting LDL-C > 2mmol/l, who are able to attain the…
- Trial name
- NCT00462748
- Testing
- ezetimibe (+) simvastatin, Comparator: atorvastatin, Comparator: rosuvastatin
- Volunteers
- 786 people
- Sponsor
- Organon and Co
Hypercholesterolemia
A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)
Prevalence of metabolic syndrome in korea is increasing. There is no clinical trial targeting on such increasing populations like metabolic syndrome patients with Vytorin® in korea.
- Trial name
- NCT00496730
- Testing
- simvastatin (+) ezetimibe, Comparator: atorvastatin
- Volunteers
- 256 people
- Sponsor
- Organon and Co
Hypercholesterolemia
A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)
A multicenter study to evaluate the safety and efficacy of ezetimibe/simvastatin versus atorvastatin in elderly patients with high cholesterol at high or moderately high risk for coronary heart disease.
- Trial name
- NCT00535405
- Testing
- Atorvastatin 10 mg, Ezetimibe 10 mg/simvastatin 20 mg, Atorvastatin 20 mg
- Volunteers
- 1,289 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40).
- Trial name
- NCT00782184
- Testing
- ezetimibe/simvastatin 10/40, atorvastatin 40 mg, atorvastatin 20 mg
- Volunteers
- 250 people
- Sponsor
- Organon and Co
Cardiovascular Disorder, Diabetes Mellitus
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
The purpose of this study is to determine the efficacy of switching to a combination tablet ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin dose in those patients who have cardiovascular…
- Trial name
- NCT00862251
- Testing
- ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Hypercholesterolemia
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe [EZ] 10 mg/Atorvastatin [Atora] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg alone when administered to Japanese participants with…
- Trial name
- NCT02550288
- Testing
- Ezetimibe 10 mg, Atorvastatin 10 mg, Diet control/Daily Exercise
- Volunteers
- 309 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants.
- Trial name
- NCT03768427
- Testing
- EZ 10 mg/Ator 10 mg, EZ 10 mg/Ator 20 mg, Atorvastatin
- Where
- 30 sites in China
- Volunteers
- 454 people
- Sponsor
- Organon and Co
Hypercholesterolemia
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
To Evaluate and Compare the Efficacy and Safety of Ezetimibe Plus Atorvastatin Versus Atorvastatin in Hypercholesterolemic Patients at High Risk for Coronary Heart Disease Not Adequately Controlled on Atorvastatin 40 mg.
- Trial name
- NCT00276484
- Testing
- atorvastatin, ezetimibe
- Volunteers
- 579 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of…
- Trial name
- NCT00418834
- Testing
- ezetimibe and atorvastatin, atorvastatin
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Hypercholesterolemia
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately…
- Trial name
- NCT00276458
- Testing
- Comparator: atorvastatin, Comparator: ezetimibe
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia
1PC002 is a newly developed synthetic and highly potent HMG-CoA reductase inhibitor. Its active compound, pitavastatin has recently been approved by US FDA for indications of primary hypercholesterolemia and combined…
- Trial name
- NCT01710007
- Testing
- 1PC002, Lipitor
- Where
- 8 sites in Taiwan
- Volunteers
- 202 people
- Sponsor
- Orient Pharma Co., Ltd.